Ponatinib Hydrochloride
- Catalog NO.：A894741
- CAS No. : 1114544-31-8
- Molecular Formula：C29H28ClF3N6O
- Molecular Weight： 569.02
1. Please click the
to confirm the discount and stock quantity.2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
| CAS Number | 1114544-31-8 | Appearance | Light yellow powder |
| Catalog Number | A894741 | MDL Number | MFCD28656903 |
| Molecular Formula | C29H28ClF3N6O | Molecular Weight | 569.02 |
| Boiling Point | Melting Point | ||
| Flash Point | Density | ||
| Synonyms | 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride | ||
| Storage Condition | Store in a tightly closed container,in a cool and dry place | ||
Safety
| GHS Pictogram |
|
||
| Signal Word | Warning | UN Number | |
| Hazard Statements | H302;H315;H319;H335 | Class | |
| Precautionary Statements | P261;P305+P351+P338 | Packing Group | |
Description
|
Ponatinib, also known as AP24534 is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors. Ponatinib was approved in 2012. |
